Compare Blackrock Inc (BLK) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Blackrock Inc vs TransMedics Group Inc — how do they compare? Blackrock Inc trades at $1,182 (market cap $179.79B), while TransMedics Group Inc trades at $89.47 (market cap $3.02B). The key difference: Blackrock Inc is far larger — about 59.5× TransMedics Group Inc's market cap, and Blackrock Inc pays a 1.97% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals.
| BLK | TMDX | |
|---|---|---|
Market Cap | $179.79B | $3.02B |
Volume | 641,547 | — |
Sector | Financials | Technology |
52-Week High | $1.20K | $150.42 |
52-Week Low | $922.90 | $61.99 |
Enterprise Value | $180.89B | $3.41B |
Dividend Yield | 1.97% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BlackRock (BLK) trades at $1,182.84, up 2.96% in 24 hours, with a bullish technical signal and strong analyst consensus. The stock shows robust fundamentals, including a 24.09% net income margin and consistent earnings beats in recent quarters. Recent news highlights strategic partnerships, such as a $500 billion AI financing initiative with Nvidia and others, while legal investigations into mutual funds pose a risk.
The outlook remains positive due to earnings momentum and institutional support, but risks include regulatory scrutiny and volatile cash flows. Wall Street's average price target of $1,350 suggests upside potential, though overbought RSI levels indicate near-term caution.
TransMedics Group (TMDX) trades at $87.02, down 2.62% on the day, amid mixed earnings performance. The stock shows strong profitability with a 22.69% net margin and 36.28% ROE, but recent quarters saw misses on EPS expectations. Technicals are bullish with moving averages supporting upside, while oscillators signal caution. Recent news highlights an ongoing legal investigation into fiduciary duties by company directors.
The outlook is cautiously optimistic with a consensus price target of $99.57 implying 14% upside, supported by bullish analyst ratings. Key risks include earnings volatility, rising costs impacting margins, and potential legal overhangs from the fiduciary investigation. Revenue growth remains a positive catalyst, but investors should monitor execution against future guidance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Blackrock Inc
BlackRock, Inc. provides investment management services to institutional clients and to retail investors through various investment vehicles. The Company manages funds, as well as offers risk management services. BlackRock serves governments, companies, and foundations worldwide.
Read more on BLK →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
